Navigation Links
Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
Date:10/26/2007

(BRONX, NY) -- Three researchers at the Albert Einstein College of Medicine have been awarded grants from the Breast Cancer Research Foundation (BCRF). Drs. Thomas Rohan, Susan Horwitz and Rachel Hazan each received grants from the BCRF in its ongoing effort to support the advancement of breast cancer research. At the heart of the BCRFs generosity is its mission, which is to achieve prevention and a cure for breast cancer by providing critical funding for innovative clinical and genetic research at leading medical centers worldwide, while also increasing public awareness about good breast health.

Dr. Rohan, professor and chair of epidemiology and population health at Einstein, received $250,000 to carry out gene expression profilingusing so-called gene chipson women at risk of developing breast cancer. Using a technique that he and colleagues developed for extracting and storing RNA from breast tissue, Dr. Rohan will focus his efforts on women with benign breast disease (BDD), since women with this condition have an increased risk for breast cancer. For those BDD patients who eventually develop breast cancer, gene-expression profiles may help to predict clinical outcomes and identify those patients most likely to respond to therapy. Dr. Rohan and his colleagues have already established a multi-center cohort of more than 25,000 women who have undergone biopsies for BDD, and these breast tissue samples will be used in the study.

Dr. Horwitz, Falkenstein Professor of Cancer Research and co-chair of molecular pharmacology at Einstein, received $225,000 to study epigenetic changes (i.e., switching genes on and off in ways that dont involve changes in DNA sequence) in breast cancer cells that may help pinpoint why some breast tumors become drug-resistant. In particular, she will study whether epigenetic mechanisms cause cells to become resistant to Taxol, a drug she helped discover that has proven highly effective in treating breast cancer. Her work could lead to new drugs that reverse drug resistance and make breast tumors more sensitive to Taxol.

Dr. Hazan, associate professor of pathology at Einstein, received $225,000 to support her research effort to eradicate mestastasizing tumor cells. She will collaborate with Dr. Larry Norton of the Memorial Sloan-Kettering Cancer Center to determine the mechanism of action of the protein N-cadherin, which is produced by aggressive breast tumors and stimulates the spread of those tumors. The team will also look for potential drugs that can target this protein, with the ultimate aim of expanding the available options for treating late-stage breast cancer.


'/>"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Einstein researchers identify new way that bacteria develop resistance to antibiotics
2. Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell
3. Feinstein researchers identify intelligence gene
4. Study by Einstein researchers could lead to a novel strategy for treating obesity
5. Einstein researchers take the pulse of a gene in living cells
6. Einstein researchers demonstrate a novel approach to treating AIDS
7. Einsteins tea leaves inspire new blood separation technique
8. Researchers discover way to make cells in the eye sensitive to light
9. Researchers find how protein allows insects to detect and respond to pheromones
10. Researchers Uncover Key Step In Manufacture of Memory Protein
11. NYU researchers simulate molecular biological clock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... ... May 25, 2016 , ... ... became double board-certified in surgery and surgery of the hand by the National ... no stranger to going above and beyond in his pursuit of providing the ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. ... the company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar ... FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is ...
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and across ... South Texas Blood & Tissue Center, blood donations are on the decline. In fact, donations ... are down 21 percent in South Texas in the last four years alone. , There ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... and services based in Aurora, Ohio, has broken ground on a new building ... Research Triangle Park area, this new location solidifies a commitment to business in ...
Breaking Biology Technology: